Obesity is now reaching epidemic proportions in both developed and developing countries
and is affecting not only adults but also children and adolescents. Over the last 20 years, …

… David CW Lau … In addition, since weight losses achieved with lifestyle intervention are
modest and recidivism rates are high (Lau 2007; Lau DC 2007), there is potential for even …

Atherosclerotic disease remains the leading cause of death in industrialized nations despite
major advances in its diagnosis, treatment, and prevention. The increasing epidemic of …

Background Obesity is a chronic disease with serious health consequences, but weight loss
is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide…

This guideline update reflects substantial advances in the epidemiology, determinants,
pathophysiology, assessment, prevention and treatment of obesity, and shifts the focus of obesity …

Objective To summarise the long term efficacy of anti-obesity drugs in reducing weight and
improving health status. Design Updated meta-analysis of randomised trials. Data sources …

Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In …

Background Cagrilintide, a long-acting amylin analogue, and semaglutide 2·4 mg, a glucagon-like
peptide-1 analogue, are both being investigated as options for weight management. …

Global obesity rates have increased steadily in both developed and emerging countries
over the past several decades with little signs of slowing down. Over 1.5 billion people …

Background Despite the increased risk of cardiovascular disease and type 2 diabetes
associated with excess bodyweight, development of a clinically meaningful metric for health …